MX2022005836A - Formulacion estable de anticuerpos acuosos. - Google Patents
Formulacion estable de anticuerpos acuosos.Info
- Publication number
- MX2022005836A MX2022005836A MX2022005836A MX2022005836A MX2022005836A MX 2022005836 A MX2022005836 A MX 2022005836A MX 2022005836 A MX2022005836 A MX 2022005836A MX 2022005836 A MX2022005836 A MX 2022005836A MX 2022005836 A MX2022005836 A MX 2022005836A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody formulation
- stable aqueous
- tfpi antibody
- aqueous anti
- tfpi
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con el campo de las formulaciones farmacéuticas de anticuerpos. Específicamente, la presente invención se relaciona con una formulación líquida estable de anticuerpos y su preparación y uso farmacéutico. Esta invención se ejemplifica mediante una formulación acuosa de un anticuerpo anti-Inhibidor de la Vía del Factor Tisular (TFPI).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962934781P | 2019-11-13 | 2019-11-13 | |
US202063081409P | 2020-09-22 | 2020-09-22 | |
PCT/IB2020/060571 WO2021094917A1 (en) | 2019-11-13 | 2020-11-10 | Stable aqueous anti-tfpi antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005836A true MX2022005836A (es) | 2022-06-09 |
Family
ID=73790141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005836A MX2022005836A (es) | 2019-11-13 | 2020-11-10 | Formulacion estable de anticuerpos acuosos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230035617A1 (es) |
EP (1) | EP4058061A1 (es) |
JP (1) | JP2021088548A (es) |
KR (1) | KR20220100634A (es) |
CN (1) | CN114786717A (es) |
AU (1) | AU2020385048A1 (es) |
BR (1) | BR112022007635A2 (es) |
CA (1) | CA3160806A1 (es) |
IL (1) | IL292493A (es) |
MX (1) | MX2022005836A (es) |
WO (1) | WO2021094917A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2745317C (en) * | 2008-12-22 | 2019-03-05 | Ida Hilden | Antibodies against tissue factor pathway inhibitor |
KR20120130757A (ko) * | 2010-02-26 | 2012-12-03 | 노보 노르디스크 에이/에스 | 안정한 항체 함유 조성물 |
CA2800188A1 (en) * | 2010-05-28 | 2011-12-01 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US10894083B2 (en) * | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
IL302353A (en) * | 2015-08-19 | 2023-06-01 | Pfizer | TFPI inhibitory antibodies and their uses |
WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
EP3761954A1 (en) * | 2018-03-07 | 2021-01-13 | Pfizer Inc | Anti-pd-1 antibody compositions |
-
2020
- 2020-11-10 KR KR1020227019650A patent/KR20220100634A/ko unknown
- 2020-11-10 MX MX2022005836A patent/MX2022005836A/es unknown
- 2020-11-10 IL IL292493A patent/IL292493A/en unknown
- 2020-11-10 AU AU2020385048A patent/AU2020385048A1/en active Pending
- 2020-11-10 BR BR112022007635A patent/BR112022007635A2/pt unknown
- 2020-11-10 WO PCT/IB2020/060571 patent/WO2021094917A1/en unknown
- 2020-11-10 CN CN202080079050.7A patent/CN114786717A/zh active Pending
- 2020-11-10 EP EP20821374.4A patent/EP4058061A1/en active Pending
- 2020-11-10 US US17/755,573 patent/US20230035617A1/en active Pending
- 2020-11-10 CA CA3160806A patent/CA3160806A1/en active Pending
- 2020-11-12 JP JP2020188526A patent/JP2021088548A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021094917A1 (en) | 2021-05-20 |
JP2021088548A (ja) | 2021-06-10 |
KR20220100634A (ko) | 2022-07-15 |
US20230035617A1 (en) | 2023-02-02 |
BR112022007635A2 (pt) | 2022-07-12 |
CN114786717A (zh) | 2022-07-22 |
IL292493A (en) | 2022-06-01 |
CA3160806A1 (en) | 2021-05-20 |
AU2020385048A1 (en) | 2022-06-02 |
EP4058061A1 (en) | 2022-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009275A (es) | Composiciones de anticuerpo anti-pd-1. | |
MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
MX2017009759A (es) | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. | |
PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
MX2017010400A (es) | Formulacion liquida estable para anticuerpos monoclonales. | |
MX2022001146A (es) | Formulaciones de anticuerpos anti-pvrig y sus usos. | |
CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
EA201291089A1 (ru) | Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций | |
EA202192405A1 (ru) | Составы антител против il-36r | |
CR20210435A (es) | Formulación de anticuerpos terapéuticos | |
MX2021011995A (es) | Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso. | |
EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
CO2020013571A2 (es) | Formulaciones estables de anticuerpos terapéuticos | |
BR112021019959A2 (pt) | Anticorpo biespecífico, e, formulação farmacêutica | |
MX2022005836A (es) | Formulacion estable de anticuerpos acuosos. | |
MX2021005015A (es) | Formulaciones farmaceuticas acuosas. | |
MX2020010679A (es) | Formulacion solida de mezclas insecticidas. | |
ECSP21079422A (es) | Método para preparar formulaciones de péptidos estables | |
JOP20220045A1 (ar) | تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها | |
MX2022001805A (es) | Formulaciones de anticuerpos anti-esclerostina. | |
EA202193054A1 (ru) | Стабильные композиции альбувиртида | |
PL424999A1 (pl) | Farmaceutycznie akceptowalna sól 5-(4-chlorofenylo)-6-etylo-2,4- pirymidynodiaminy | |
MX2023004533A (es) | Formulaciones de anticuerpos anti-siglec-8. |